These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 17498071)

  • 1. Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B.
    Lambert T; Recht M; Valentino LA; Powell JS; Udata C; Sullivan ST; Roth DA
    Haemophilia; 2007 May; 13(3):233-43. PubMed ID: 17498071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of investigator-prescribed BeneFIX prophylaxis in children less than 6 years of age with severe haemophilia B.
    Monahan PE; Liesner R; Sullivan ST; Ramirez ME; Kelly P; Roth DA
    Haemophilia; 2010 May; 16(3):460-8. PubMed ID: 20059559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine in previously treated patients with severe haemophilia B.
    Serban M; Skotnicki AB; Colovic M; Jinca C; Klukowska A; Laguna P; Wolf DM
    Haemophilia; 2012 Mar; 18(2):175-81. PubMed ID: 21812863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head-to-head comparison of the pharmacokinetic profiles of a high-purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia B.
    Lissitchkov T; Matysiak M; Zavilska K; Laguna P; Gercheva L; Antonov A; Moret A; Caunedo P; Aznar JA; Woodward MK; Páez A
    Haemophilia; 2013 Sep; 19(5):674-8. PubMed ID: 23647607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B.
    Lissitchkov T; Matysiak M; Zavilska K; Laguna P; Gercheva L; Antonov A; Cabrera N; Aznar JA; Woodward MK; Páez A
    Haemophilia; 2011 Jul; 17(4):590-6. PubMed ID: 21299747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
    Aznar JA; Cabrera N; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañés M; Páez AM; Lissitchkov T
    Haemophilia; 2009 Nov; 15(6):1243-8. PubMed ID: 19659601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
    Goudemand J; Peynet J; Chambost H; Négrier C; Briquel ME; Claeyssens S; Derlon-Borel A; Guérois C; Caron C; Scherrmann JM; Debray M; Bridey F
    Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.
    Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Rusen L; Lamas JL; Oh MS; Chapman M; Fritsch S; Pavlova BG; Wong WY; Abbuehl BE
    Haemophilia; 2014 Jan; 20(1):15-24. PubMed ID: 23834666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B.
    Lissitchkov T; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañes M; Paez A
    Haemophilia; 2010 Mar; 16(2):240-6. PubMed ID: 20015218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B.
    Kavakli K; Smith L; Kuliczkowski K; Korth-Bradley J; You CW; Fuiman J; Zupančić-Šalek S; Abdul Karim F; Rendo P
    Haemophilia; 2016 May; 22(3):381-8. PubMed ID: 26823276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, Efficacy, and Safety of Nonacog Alfa in Previously Treated Patients with Moderately Severe to Severe Hemophilia B.
    Korth-Bradley JM; Rendo P; Smith L; Altisent C
    Clin Ther; 2016 Apr; 38(4):936-44. PubMed ID: 26969334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.
    Collins PW; Quon DVK; Makris M; Chowdary P; Kempton CL; Apte SJ; Ramanan MV; Hay CRM; Drobic B; Hua Y; Babinchak TJ; Gomperts ED
    Haemophilia; 2018 Jan; 24(1):104-112. PubMed ID: 28833808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis.
    Martinowitz U; Shapiro A; Quon DV; Escobar M; Kempton C; Collins PW; Chowdary P; Makris M; Mannucci PM; Morfini M; Valentino LA; Gomperts E; Lee M
    Haemophilia; 2012 Nov; 18(6):881-7. PubMed ID: 22764744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant factor IX.
    White GC; Beebe A; Nielsen B
    Thromb Haemost; 1997 Jul; 78(1):261-5. PubMed ID: 9198163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical evaluation of recombinant factor IX.
    White G; Shapiro A; Ragni M; Garzone P; Goodfellow J; Tubridy K; Courter S
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):33-8. PubMed ID: 9565165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a recombinant factor IX (Bax326) in previously treated patients with severe or moderately severe haemophilia B undergoing surgical or other invasive procedures: a prospective, open-label, uncontrolled, multicentre, phase III study.
    Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Ghandehari H; Chapman M; Fritsch S; Wong WY; Pavlova BG; Abbuehl BE
    Haemophilia; 2014 Sep; 20(5):651-8. PubMed ID: 24697870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
    Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
    Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects.
    Valentino LA; Rusen L; Elezovic I; Smith LM; Korth-Bradley JM; Rendo P
    Haemophilia; 2014 May; 20(3):398-406. PubMed ID: 24418368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery.
    Négrier C; Abdul Karim F; Lepatan LM; Lienhart A; López-Fernández MF; Mahlangu J; Pabinger I; Li Y; Wolko D; Voigt C; Jacobs I; Santagostino E
    Haemophilia; 2016 Jul; 22(4):e259-66. PubMed ID: 27333467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An ultrapure plasma-derived monoclonal antibody-purified factor IX concentrate (Nonafact®), results of phase III and IV clinical studies.
    Mauser-Bunschoten EP; Kleine Budde I; Lopaciuk S; Koopman MM; Van Der Meer FJ; Novàkovà IR; Ypma P; Van Der Linden PW; Windyga J; Strengers PF
    Haemophilia; 2011 May; 17(3):439-45. PubMed ID: 21362109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.